Lung Cancer Diagnostic And Screening Global Market Report 2025

Description

Lung cancer diagnosis and screening involve employing examinations and techniques to detect and identify lung cancer, aiming for early detection and accurate diagnosis to facilitate effective treatment planning. This process is commonly applied in the treatment of squamous cell carcinomas, adenocarcinoma, and large cell carcinoma.

The primary products associated with lung cancer diagnostics and screening include instruments, consumables, and accessories. Instruments are products utilized to analyze the results of diagnostic tests and process samples for diagnostic purposes. Various tests, such as biomarker tests, imaging tests, biopsy, and blood tests, are employed for different cancer types, including non-small cell lung cancer and small cell lung cancer. These diagnostic tools find application across diverse end-users, including hospitals, independent diagnostic laboratories, diagnostic imaging centers, cancer research institutes, and others.

The lung cancer diagnostics and screening market research report are one of a series of new reports from The Business Research Company that provides lung cancer diagnostics and screening market statistics, including lung cancer diagnostics and screening industry global market size, regional shares, competitors with a lung cancer diagnostics and screening market share, detailed lung cancer diagnostics and screening market segments, market trends and opportunities, and any further data you may need to thrive in the lung cancer diagnostics and screening industry. This lung cancer diagnostics and screening market research report deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The lung cancer diagnostic and screening market size has grown strongly in recent years. It will grow from $2.34 billion in 2024 to $2.56 billion in 2025 at a compound annual growth rate (CAGR) of 9.6%. The growth in the historic period can be attributed to growth in digital imaging, standardization of screening protocols, public health initiatives against tobacco use, establishment of cancer registries, and advancements in pathology analysis

The lung cancer diagnostic and screening market size is expected to see strong growth in the next few years. It will grow to $3.69 billion in 2029 at a compound annual growth rate (CAGR) of 9.5%. The growth in the forecast period can be attributed to increasing incidence of lung cancer, growing emphasis on early detection, expansion of high-risk screening programs, shift towards personalized medicine, government initiatives and funding. Major trends in the forecast period include emergence of novel screening modalities, advancements in biomarker testing, integration of artificial intelligence (AI), rise in liquid biopsy adoption, focus on early stage detection, and expansion of low-dose CT screening programs.

The projected increase in the prevalence of lung cancer is poised to drive the growth of the lung cancer diagnostic and screening market in the foreseeable future. Lung cancer, characterized by symptoms such as coughing, chest pain, and difficulty breathing, is a malignant disease marked by the uncontrolled proliferation of abnormal cells in lung tissues. Diagnostic and screening methods for lung cancer play a crucial role in early detection, utilizing various tests such as incisional biopsy and bronchoscopy. As of January 2023, data from the American Cancer Society indicates approximately 238,340 new cases of lung cancer in the United States, with 127,070 reported deaths. This surge in lung cancer cases underscores the significance of diagnostic and screening measures, thereby fueling the growth of the lung cancer diagnostic and screening market.

The upward trajectory of healthcare expenditures is anticipated to further propel the expansion of the lung cancer diagnostic and screening market. Healthcare expenditures encompass the total costs associated with providing and receiving medical services, treatments, and healthcare-related goods and activities. The implementation of lung cancer diagnostic and screening methods contributes to healthcare expenditures by facilitating early detection, potentially reducing long-term treatment costs, and enhancing patient outcomes. In November 2022, the Canadian Institute for Health Information (CIHI) projected a 0.8% increase in total health spending in Canada, reaching $331 billion in 2022 from $328 billion in 2021. This upward trend in healthcare expenditures is a key driver in the growth of the lung cancer diagnostic and screening market.

Key players in the lung cancer diagnostic and screening market are advancing technologies such as lung cancer tests aimed at enhancing early detection, improving diagnostic accuracy, and enabling personalized treatment strategies for patients at high risk of the disease. These lung cancer tests utilize various methods, including imaging, biomarker analysis, and cytological examinations, to identify the presence of lung cancer. For example, in December 2023, Freenome, a biotechnology company based in the United States, introduced PROACT LUNG. This trial represents a significant advancement in lung cancer screening, potentially leading to earlier detection and improved patient outcomes while addressing current shortcomings in screening practices.

Major players in the lung cancer diagnostics and screening market are strategically focused on the development of blood-based tests that leverage machine learning, specifically whole-genome machine learning. This approach involves applying machine learning algorithms to analyze and interpret comprehensive sets of genetic information, encompassing an organism's entire genome. DELFI Diagnostics Inc., a US-based developer of accessible blood-based tests, exemplified this strategy in October 2023 with the launch of FirstLook Lung. This blood test utilizes whole-genome machine learning to analyze cell-free DNA fragments, enhancing lung cancer screening with an impressive 99.7% negative predictive value (NPV). Designed for routine blood work, the test identifies individuals with potential lung cancer, including those in early stages, aiming to improve population health by addressing low uptake of low-dose computed tomography (LDCT) screening.

In January 2022, RadNet Inc., a US-based radiology company, acquired Aidence BV for an undisclosed amount. This acquisition is anticipated to strengthen RadNet Inc.'s leadership in developing and deploying artificial intelligence (AI) for improved patient care and health. It also accelerates their growth and innovation pipeline, providing automated and integrated AI oncology solutions for clinicians. Aidence BV, based in the Netherlands, is a healthcare technology company with a focus on clinical solutions for lung cancer screening and pulmonary nodule treatment.

Major companies operating in the lung cancer diagnostic and screening market include Pfizer Inc., F. Hoffmann-La Roche AG, Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., AstraZeneca Plc, Abbott Laboratories Inc., Danaher Corporation, Siemens Healthcare GmbH, FUJIFILM Corporation, Koninklijke Philips N.V., GE Healthcare Bio Sciences AB, Quest Diagnostics Incorporated, Agilent Technologies Inc., Illumina Inc., Qiagen Inc., Myriad Genetic Laboratories Inc., NeoGenomics Laboratories Inc., Canon Medical Systems Corporation, OncimmuneHoldings Plc, Broncus Medical Inc., OncoCyte, Riverain Technologies LLC, VisionGate, Foundation Medicine Inc., Biodesix,

North America was the largest region in the lung cancer diagnostic and screening market in 2024. The regions covered in the lung cancer diagnostic and screening market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the lung cancer diagnostic and screening market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The lung cancer diagnosis and screening market consists of revenues earned by entities by providing positron emission tomography (PET) scanners, and bronchoscopy. The market value includes the value of related goods sold by the service provider or included within the service offering. The lung cancer diagnosis and screening market also includes sales of products such as liquid biopsy kits, molecular testing kits, and biopsy tools. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Lung Cancer Diagnostic And Screening Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on lung cancer diagnostic and screening market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for lung cancer diagnostic and screening ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The lung cancer diagnostic and screening market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Product: Instruments; Consumables And Accessories
2) By Test: Biomarkers Tests; Imaging Test; Biopsy; Blood Test; Other Tests
3) By Cancer Type: Non-Small Cell Lung Cancer; Small Cell Lung Cancer
4) By End User: Hospital; Independent Diagnostic Laboratories; Diagnostic Imaging Centers; Cancer Research Institutes; Other End-Users
Subsegments:
1) By Instruments: Imaging Devices; Biopsy Devices; Bronchoscopy Systems
2) By Consumables And Accessories: Biopsy Needles; Reagents And Assays; Imaging Contrast Agents; Patient Preparation Equipment; Sample Collection Kits; Laboratory Supplies
Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche AG; Bristol-Myers Squibb Company; Thermo Fisher Scientific Inc.; AstraZeneca Plc
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r25074

1. Executive Summary

2. Lung Cancer Diagnostic And Screening Market Characteristics

3. Lung Cancer Diagnostic And Screening Market Trends And Strategies

4. Lung Cancer Diagnostic And Screening Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Lung Cancer Diagnostic And Screening Growth Analysis And Strategic Analysis Framework

5.1. Global Lung Cancer Diagnostic And Screening PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Lung Cancer Diagnostic And Screening Market Growth Rate Analysis
5.4. Global Lung Cancer Diagnostic And Screening Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Lung Cancer Diagnostic And Screening Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Lung Cancer Diagnostic And Screening Total Addressable Market (TAM)

6. Lung Cancer Diagnostic And Screening Market Segmentation

6.1. Global Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Instruments
Consumables And Accessories
6.2. Global Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Biomarkers Tests
Imaging Test
Biopsy
Blood Test
Other Tests
6.3. Global Lung Cancer Diagnostic And Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Non-Small Cell Lung Cancer
Small Cell Lung Cancer
6.4. Global Lung Cancer Diagnostic And Screening Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital
Independent Diagnostic Laboratories
Diagnostic Imaging Centers
Cancer Research Institutes
Other End-Users
6.5. Global Lung Cancer Diagnostic And Screening Market, Sub-Segmentation Of Instruments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Imaging Devices
Biopsy Devices
Bronchoscopy Systems
6.6. Global Lung Cancer Diagnostic And Screening Market, Sub-Segmentation Of Consumables And Accessories, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Biopsy Needles
Reagents And Assays
Imaging Contrast Agents
Patient Preparation Equipment
Sample Collection Kits
Laboratory Supplies

7. Lung Cancer Diagnostic And Screening Market Regional And Country Analysis

7.1. Global Lung Cancer Diagnostic And Screening Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Lung Cancer Diagnostic And Screening Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Lung Cancer Diagnostic And Screening Market

8.1. Asia-Pacific Lung Cancer Diagnostic And Screening Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Lung Cancer Diagnostic And Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Lung Cancer Diagnostic And Screening Market

9.1. China Lung Cancer Diagnostic And Screening Market Overview
9.2. China Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Lung Cancer Diagnostic And Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Lung Cancer Diagnostic And Screening Market

10.1. India Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Lung Cancer Diagnostic And Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Lung Cancer Diagnostic And Screening Market

11.1. Japan Lung Cancer Diagnostic And Screening Market Overview
11.2. Japan Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Lung Cancer Diagnostic And Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Lung Cancer Diagnostic And Screening Market

12.1. Australia Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Lung Cancer Diagnostic And Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Lung Cancer Diagnostic And Screening Market

13.1. Indonesia Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Lung Cancer Diagnostic And Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Lung Cancer Diagnostic And Screening Market

14.1. South Korea Lung Cancer Diagnostic And Screening Market Overview
14.2. South Korea Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Lung Cancer Diagnostic And Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Lung Cancer Diagnostic And Screening Market

15.1. Western Europe Lung Cancer Diagnostic And Screening Market Overview
15.2. Western Europe Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Lung Cancer Diagnostic And Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Lung Cancer Diagnostic And Screening Market

16.1. UK Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Lung Cancer Diagnostic And Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Lung Cancer Diagnostic And Screening Market

17.1. Germany Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Lung Cancer Diagnostic And Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Lung Cancer Diagnostic And Screening Market

18.1. France Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Lung Cancer Diagnostic And Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Lung Cancer Diagnostic And Screening Market

19.1. Italy Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Lung Cancer Diagnostic And Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Lung Cancer Diagnostic And Screening Market

20.1. Spain Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Lung Cancer Diagnostic And Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Lung Cancer Diagnostic And Screening Market

21.1. Eastern Europe Lung Cancer Diagnostic And Screening Market Overview
21.2. Eastern Europe Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Lung Cancer Diagnostic And Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Lung Cancer Diagnostic And Screening Market

22.1. Russia Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Lung Cancer Diagnostic And Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Lung Cancer Diagnostic And Screening Market

23.1. North America Lung Cancer Diagnostic And Screening Market Overview
23.2. North America Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Lung Cancer Diagnostic And Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Lung Cancer Diagnostic And Screening Market

24.1. USA Lung Cancer Diagnostic And Screening Market Overview
24.2. USA Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Lung Cancer Diagnostic And Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Lung Cancer Diagnostic And Screening Market

25.1. Canada Lung Cancer Diagnostic And Screening Market Overview
25.2. Canada Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Lung Cancer Diagnostic And Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Lung Cancer Diagnostic And Screening Market

26.1. South America Lung Cancer Diagnostic And Screening Market Overview
26.2. South America Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Lung Cancer Diagnostic And Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Lung Cancer Diagnostic And Screening Market

27.1. Brazil Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Lung Cancer Diagnostic And Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Lung Cancer Diagnostic And Screening Market

28.1. Middle East Lung Cancer Diagnostic And Screening Market Overview
28.2. Middle East Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Lung Cancer Diagnostic And Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Lung Cancer Diagnostic And Screening Market

29.1. Africa Lung Cancer Diagnostic And Screening Market Overview
29.2. Africa Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Lung Cancer Diagnostic And Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Lung Cancer Diagnostic And Screening Market Competitive Landscape And Company Profiles

30.1. Lung Cancer Diagnostic And Screening Market Competitive Landscape
30.2. Lung Cancer Diagnostic And Screening Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. AstraZeneca Plc Overview, Products and Services, Strategy and Financial Analysis

31. Lung Cancer Diagnostic And Screening Market Other Major And Innovative Companies

31.1. Abbott Laboratories Inc.
31.2. Danaher Corporation
31.3. Siemens Healthcare GmbH
31.4. FUJIFILM Corporation
31.5. Koninklijke Philips N.V.
31.6. GE Healthcare Bio Sciences AB
31.7. Quest Diagnostics Incorporated
31.8. Agilent Technologies Inc.
31.9. Illumina Inc.
31.10. Qiagen Inc.
31.11. Myriad Genetic Laboratories Inc.
31.12. NeoGenomics Laboratories Inc.
31.13. Canon Medical Systems Corporation
31.14. OncimmuneHoldings Plc
31.15. Broncus Medical Inc.

32. Global Lung Cancer Diagnostic And Screening Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Lung Cancer Diagnostic And Screening Market

34. Recent Developments In The Lung Cancer Diagnostic And Screening Market

35. Lung Cancer Diagnostic And Screening Market High Potential Countries, Segments and Strategies

35.1 Lung Cancer Diagnostic And Screening Market In 2029 - Countries Offering Most New Opportunities
35.2 Lung Cancer Diagnostic And Screening Market In 2029 - Segments Offering Most New Opportunities
35.3 Lung Cancer Diagnostic And Screening Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer